The Medication Competition Act requires the Secretary of Health and Human Services to clearly identify and publish the exclusivity periods for biological drug products, which determine when generic or biosimilar alternatives can enter the market. For biological products approved after the bill becomes law, the agency must publish exclusivity information within 30 days of licensing or when the expiration date becomes known. For products already approved before the law takes effect, the agency has two years to publish this information, with a 30-day deadline applying to new exclusivity periods identified after enactment. This legislation affects pharmaceutical companies, generic manufacturers, and patients by increasing transparency around when biological drug competitors can be developed and approved. The bill aims to speed up competition in the biological drug market by making exclusivity periods publicly known, potentially helping reduce drug costs.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.